Retinal Vein Occlusion Industry Trends: Market to Cross US$ 5.5 Billion by 2034 at 6.7% CAGR

The global retinal vein occlusion market was valued at US$ 2.8 billion in 2023 and is projected to exceed US$ 5.5 billion by 2034, expanding at a CAGR of 6.7% from 2024 to 2034. The market growth is driven by the increasing prevalence of retinal disorders, rising incidence of diabetes and hypertension, growing geriatric population, advancements in ophthalmic diagnostics, and increasing adoption of anti-VEGF therapies.

👉 Get sample market research report copy today@ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=60489

Market Overview

Increasing regulatory approval for retinal vein occlusion (RVO) treatment products is expected to act as a significant driver for the RVO market over the forecast period. Regulatory approvals from authoritative bodies such as the FDA and EMA can expedite the market entry of new and innovative treatments, allowing pharmaceutical companies to bring their products to patients more quickly and efficiently

This not only accelerates commercialization but also expands the range of treatment options available to healthcare providers and patients, leading to improved patient outcomes and higher satisfaction. Additionally, regulatory approvals often enhance the credibility and trust in the safety and efficacy of these treatments, which can increase their adoption rates and influence insurance coverage and reimbursement policies, making them more accessible and affordable

For instance, in March 2024, Chugai Pharmaceutical Co., Ltd. announced that it had obtained regulatory approval from the Ministry of Health, Labour and Welfare (MHLW) for anti-VEGF/anti-Ang-2 bispecific antibody Vabysmo Intravitreal Injection 120, for an additional indication of the treatment of macular edema associated with retinal vein occlusion (RVO). Vabysmo is the first bispecific antibody in Japan for the treatment of this disease

Analysts' Viewpoint

The Retinal Vein Occlusion (RVO) market is poised for substantial growth, driven by the increasing prevalence of retinal vein occlusion. Rising awareness about the importance of early diagnosis and advanced treatment options is expected to boost market expansion. The development and approval of novel therapeutic agents, such as anti-VEGF drugs and corticosteroids, are enhancing treatment efficacy and improving patient outcomes, further propelling market growth.

However, the high costs associated with these advanced treatments and the limited availability of skilled healthcare professionals, particularly in developing regions, pose significant restraints. Market trends indicate a growing emphasis on personalized medicine and the integration of telemedicine services to enhance access to care.

Additionally, ongoing clinical trials and research into gene therapy and regenerative medicine are opening new opportunities for innovation. Despite these challenges, the overall outlook for the RVO market remains positive, with a strong focus on advancing treatment modalities and improving patient care.

Analysis of Key Players

The competitive landscape is characterized by innovative ophthalmic therapies, clinical research, product lifecycle management, diagnostic advancements, and strategic collaborations.

Leading companies operating in the global retinal vein occlusion market include:

• Roche
• Novartis
• Regeneron Pharmaceuticals
• Bayer
• AbbVie
• Bausch + Lomb
• Alimera Sciences
• Karyopharm Therapeutics
• Other Prominent Players

Strategic investments in retinal therapeutics, anti-VEGF treatments, long-acting drug delivery, diagnostic imaging, and clinical development remain key competitive strategies among market participants.

Recent Developments (2023-2024)

• In May 2023, Bayer conducted a phase III QUASAR study to evaluate the efficacy and safety of aflibercept 8 mg in treating macular edema due to retinal vein occlusion. The study enrolled around 800 patients in 27 countries and measure changes in the best corrected visual acuity. The study follows regulatory authorization applications for aflibercept 8 mg in the EU and Japan.

• In October 2023, Genentech received approval by the FDA for treating retinal vein occlusion (RVO), age-related macular degeneration (AMD), and diabetic macular edema. The drug, Vabysmo, is the first and only bispecific antibody approved for the eye, showing early and sustained vision improvements as compared to aflibercept.

• In August 2023, Regeneron Pharmaceuticals, Inc. reported that the U.S. Food and Drug Administration (FDA) granted approval for EYLEA HD (aflibercept) Injection 8 mg as a treatment option for individuals with wet age-related macular degeneration (wAMD), diabetic macular edema (DME), and diabetic retinopathy (DR).

👉 Discuss Implications for Your Industry Request Sample Market Research Report PDF@ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=60489

Key Developments & Trends

• Anti-VEGF Therapy: Anti-vascular endothelial growth factor treatments remain a major therapeutic approach for retinal edema associated with RVO.

• Advanced Retinal Imaging: OCT and other imaging technologies are improving diagnosis and monitoring.

• Long-acting Treatments: Development of therapies with longer dosing intervals can reduce treatment burden.

• Growing Geriatric Population: Aging populations are increasing the prevalence of vascular and retinal disorders.

• Risk-factor Management: Greater awareness of diabetes, hypertension, and cardiovascular risk is supporting early detection and disease management.
Challenges

• Treatment Burden: Repeated intravitreal injections can create challenges for patients and healthcare providers.

• Disease Recurrence: Some patients may require ongoing monitoring and repeated treatment.

• High Treatment Costs: Long-term retinal disease management can place financial pressure on patients and healthcare systems.

• Limited Awareness: Delayed diagnosis can increase the risk of vision complications.

Opportunities

• Long-acting Drug Delivery: Therapies that reduce injection frequency offer significant market opportunities.

• Advanced Diagnostics: Improvements in OCT, angiography, and AI-assisted retinal imaging can enhance disease detection.

• Combination Therapies: Combining different treatment approaches may improve outcomes in selected patient populations.

• Emerging Markets: Expanding ophthalmic healthcare infrastructure creates opportunities for diagnosis and treatment in developing regions.

Market Segmentation

• Disease Type

o Central Retinal Vein Occlusion
o Branch Retinal Vein Occlusion

• Treatment Type

o Pharmacological Treatment
 Anti-vascular endothelial growth factor (anti-VEGF) Drugs
 Corticosteroid Drugs

o Laser Treatment
 Panretinal Photocoagulation
 Focal Laser
o Vitrectomy

• End-user

o Hospitals and Ambulatory Surgical Centers
o Ophthalmology Clinics
o Retail Pharmacies
o Others

Conclusion

The global retinal vein occlusion market is expected to witness steady growth through 2034, driven by the rising prevalence of retinal vascular disorders, increasing geriatric population, growing burden of diabetes and hypertension, and continued advancements in ophthalmic diagnostics and therapeutics. The development of long-acting treatments, advanced retinal imaging, personalized treatment approaches, and novel drug delivery technologies will further support market development. As awareness and access to retinal disease diagnosis improve, demand for effective RVO management solutions is expected to increase globally.

👉 To buy this comprehensive market research report, click here to inquire@ https://www.transparencymarketresearch.com/checkout.php?rep_id=60489<ype=S

About Transparency Market Research

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact:

Abhishek Budholiya
Transparency Market Research Inc.
State Tower, 90 State Street, Suite 700,
Albany NY - 12207, United States
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com

This release was published on openPR.